Verrica Pharmaceuticals to Present at May 2024 Investor Conferences

WEST CHESTER, Pa., May 09, 2024 — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), specializing in dermatology therapeutics, has announced that its President and Chief Executive Officer, Ted White, will be presenting at two upcoming investor conferences. Ted White is scheduled to speak at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:05 p.m. ET in New York, NY. Following this, he will present at the HCW BioConnect Conference on Monday, May 20, 2024, at 10:00 a.m. ET, also in New York, NY. Webcasts of these presentations will be accessible via the Investors/Presentations & Events section on the Verrica website and will remain available for 90 days after the events.

Verrica Pharmaceuticals Inc. focuses on developing treatments for skin diseases that require medical intervention. On July 21, 2023, the company's product YCANTH® (cantharidin) received FDA approval as the first treatment for molluscum contagiosum, a contagious viral skin infection affecting about 6 million people in the United States, primarily children. YCANTH (VP-102) is currently being developed for the treatment of common and external genital warts, which remain significant unmet needs in dermatology.

Additionally, Verrica is advancing VP-103, another cantharidin-based product candidate, aimed at treating plantar warts. The company has also secured a global license agreement with Lytix Biopharma AS to develop and market VP-315 (formerly known as LTX-315 and VP-LTX-315). This candidate is intended for the treatment of non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.